pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2021-31-5-562-570pulmo-2876Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALПостковидное состояние у взрослых и детейPost-covid condition in adults and childrenhttps://orcid.org/0000-0002-5518-9301БаймухамбетоваД. В.BaimukhambetovaDina V.

Баймухамбетова Дина Владимировна – студентка

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Dina V. Baimukhambetova, student

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

dbaimukhambietova@bk.ruhttps://orcid.org/0000-0001-7723-4946ГоринаА. О.GorinaAnastasia O.

Горина Анастасия Олеговна – студентка

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Anastasia O. Gorina, student

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

stasyagorina09@gmail.comhttps://orcid.org/0000-0001-9552-3936РумянцевМ. А.RumyantsevMikhail A.

Румянцев Михаил Анатольевич – студент

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Mikhail A. Rumyantsev, student

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

listorezok@gmail.comhttps://orcid.org/0000-0002-7074-7922ШихалеваА. А.ShikhalevaAnastasia A.

Шихалева Анастасия Алексеевна – студентка

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Anastasia A. Shikhaleva, student

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

masiaka1994@gmail.comhttps://orcid.org/0000-0002-4218-4456Эль-ТаравиЯ. А.El-TaraviYasmin A.

Эль-Тарави Ясмин Ахмед Али – студент

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Yasmin A. El-Taravi, student

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

yasmin.el-taravi@bk.ruhttps://orcid.org/0000-0002-8007-5314БондаренкоЕ. Д.BondarenkoElena D.

Бондаренко Елена Дмитриевна – ассистент кафедры педиатрии и детских инфекционных болезней Клинического института детского здоровья имени Н.Ф. Филатова

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Elena D. Bondarenko, Assistant, Department of Pediatrics and Paediatric Infectious Diseases, N.F.Filatov Clinical Institute of Children’s Health

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

alenkabond@gmail.comhttps://orcid.org/0000-0001-6512-1629КапустинаВ. А.KapustinaValentina A.

Капустина Валентина Андреевна – к. м. н., доцент кафедры факультетской терапии № 1 Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Valentina A. Kapustina, Candidate of Medicine, Associate Professor, Department of Faculty Therapy No.1, N.V.Sklifosovsky Institute of Clinical Medicine

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

kapustina.valentina.a@gmail.comhttps://orcid.org/0000-0001-9652-6856МунблитД. Б.MunblitDaniil B.

Мунблит Даниил Борисович – доктор медицины, PhD по педиатрии, профессор кафедры педиатрии и детских инфекционных болезней Клинического института детского здоровья имени Н.Ф. Филатова

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 256-57-72

Daniil B. Munblit, MD, PhD, Professor, Department of Pediatrics andPaediatric Infectious Diseases, N.F.Filatov Clinical Institute of Children’s Health

ul. Trubetskaya 8, build. 2, Moscow, 119991

tel.: (499) 256-57-72

daniel.munblit08@imperial.ac.ukФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохраненияРоссияFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of HealthcareRussian Federation202120102021315562570Copyright © Баймухамбетова Д.В., Горина А.О., Румянцев М.А., Шихалева А.А., Эль-Тарави Я.А., Бондаренко Е.Д., Капустина В.А., Мунблит Д.Б., 20212021Баймухамбетова Д.В., Горина А.О., Румянцев М.А., Шихалева А.А., Эль-Тарави Я.А., Бондаренко Е.Д., Капустина В.А., Мунблит Д.Б.Baimukhambetova D.V., Gorina A.O., Rumyantsev M.A., Shikhaleva A.A., El-Taravi Y.A., Bondarenko E.D., Kapustina V.A., Munblit D.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2876

Несмотря на впечатляющий прогресс в диагностике и лечении острой фазы COVID-19, первые данные, касающиеся последствий перенесенной инфекции, только появляются в научной литературе. Для описания широкого спектра проявлений перенесенного острого COVID-19 Всемирной организацией здравоохранения предложен термин «постковидное состояние» (ПКС). При наличии > 200 млн подтвержденных случаев COVID-19 ПКС рискует стать проблемой на многие годы для миллионов людей, переживших COVID-19 во всем мире. Сравнительно небольшое число исследований проводилось по данным первичного звена здравоохранения, крайне малочислены работы, посвященные исключительно детям и подросткам.

Целью исследования явилось формирование представления основных данных о ПКС. По результатам анализа статей, опубликованных в международных рецензируемых журналах, а также клинических протоколов, установлено, что ПКС характеризуется крайне большим разнообразием системных, сердечно-легочных, желудочно-кишечных, неврологических и психосоциальных симптомов.

Заключение. Несмотря на то, что представить распространенность ПКС на сегодняшний день невозможно в связи с методологическими недостатками существующих исследований, данная проблема, без сомнений, важна для здравоохранения, при этом для выявления оптимальных подходов к профилактике и лечению ПКС необходимы дополнительные обсервационные и интервенционные исследования.

Despite the impressive progress in diagnosis and management of acute COVID-19, data regarding the consequences of this infection are just emerging. The World Health Organization has proposed the term post-COVID condition (PCC) to describe the wide range of sequelae of acute COVID-19. With more than 200 million confirmed cases of COVID-19, PCC may develop into a major problem for many years to come for the millions of COVID-19 survivors worldwide. Few studies were conducted in primary care, and very few studies have focused exclusively on children and adolescents.

Objective

Objective. To review existing data on PCC. Analysis of manuscripts published in peer-reviewed journals and clinical protocols. PCC is characterized by a wide range of systemic, cardio-pulmonary, gastrointestinal, neurological, and psychosocial symptoms.

Conclusion

Conclusion. Although PCC prevalence is difficult to estimate due to methodological limitations of the existing studies, there is no doubt that this problem is a significant healthcare burden. There is a need for further observational and interventional studies to establish optimal PCC prevention and management strategies.

COVID-19постковидный синдромпостковидное состояниепоследствия COVID-19новая коронавирусная инфекцияCOVID-19post-COVID syndromepost-COVID conditionsequelae of COVID-19new coronavirus infectionReferencesWorld Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/?gclid=EAIaIQobChMIxs-CobqP8wIVo0aRBR3NvAqUEAAYASABEgKQ9_D_BwEWorld Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/?gclid=EAIaIQobChMIxs-CobqP8wIVo0aRBR3NvAqUEAAYASABEgKQ9_D_BwEKobak D. Excess mortality reveals Covid’s true toll in Russia. Signif. (Oxf). 2021; 18 (1): 16–19. DOI: 10.1111/1740-9713.01486.Kobak D. Excess mortality reveals Covid’s true toll in Russia. Signif. (Oxf). 2021; 18 (1): 16–19. DOI: 10.1111/1740-9713.01486.RECOVERY Collaborative Group: Horby P., Lim W.S., Emberson J.R. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021; 384 (8): 693–704. DOI: 10.1056/NEJMoa2021436.RECOVERY Collaborative Group: Horby P., Lim W.S., Emberson J.R. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021; 384 (8): 693–704. DOI: 10.1056/NEJMoa2021436.RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397 (10285): 1637–1645. DOI: 10.1016/S0140-6736(21)00676-0.RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397 (10285): 1637–1645. DOI: 10.1016/S0140-6736(21)00676-0.Wise J. Long COVID: WHO calls on countries to offer patients more rehabilitation. BMJ. 2021; 372: n405. DOI: 10.1136/bmj.n405.Wise J. Long COVID: WHO calls on countries to offer patients more rehabilitation. BMJ. 2021; 372: n405. DOI: 10.1136/bmj.n405.Centers for Disease Control and Prevention (CDC). COVID-19. Your Health. Available at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/index.html [Assessed: August 10, 2021].Centers for Disease Control and Prevention (CDC). COVID-19. Your Health. Available at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/index.html [Assessed: August 10, 2021].Garg P., Arora U., Kumar A., Wig N. The “post-COVID” syndrome: How deep is the damage? J. Med. Virol. 2021; 2 (93): 673–674. DOI: 10.1002/jmv.26465.Garg P., Arora U., Kumar A., Wig N. The “post-COVID” syndrome: How deep is the damage? J. Med. Virol. 2021; 2 (93): 673–674. DOI: 10.1002/jmv.26465.COVID-19 rapid guideline: managing the long-term effects of COVID-19: NICE Guideline No.188. London: National Institute for Health and Care Excellence; 2020. Available at: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managingthe-longterm-effects-of-covid19-pdf-66142028400325COVID-19 rapid guideline: managing the long-term effects of COVID-19: NICE Guideline No.188. London: National Institute for Health and Care Excellence; 2020. Available at: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managingthe-longterm-effects-of-covid19-pdf-66142028400325Michelen M., Manoharan L., Elkheir N. et al. Characterising longterm Covid-19: a rapid living systematic review. medRxiv. 2020 [Preprint. Posted: August 12, 2020]. DOI: 10.1101/2020.12.08.20246025.Michelen M., Manoharan L., Elkheir N. et al. Characterising longterm Covid-19: a rapid living systematic review. medRxiv. 2020 [Preprint. Posted: August 12, 2020]. DOI: 10.1101/2020.12.08.20246025.Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–1242. DOI: 10.1001/jama.2020.2648.Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–1242. DOI: 10.1001/jama.2020.2648.Garrigues E., Janvier P., Kherabi Y. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020; 81 (6): e4–6. DOI: 10.1016/j.jinf.2020.08.029.Garrigues E., Janvier P., Kherabi Y. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020; 81 (6): e4–6. DOI: 10.1016/j.jinf.2020.08.029.Chopra V., Flanders S. A., O’Malley M. et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann. Intern. Med. 2021; 174 (4): 576–578. DOI: 10.7326/M20-5661.Chopra V., Flanders S. A., O’Malley M. et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann. Intern. Med. 2021; 174 (4): 576–578. DOI: 10.7326/M20-5661.Halpin S.J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol. 2021; 2 (93): 1013–1022. DOI: 10.1002/jmv.26368.Halpin S.J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol. 2021; 2 (93): 1013–1022. DOI: 10.1002/jmv.26368.Huang C., Huang L., Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397 (10270): 220–232. DOI: 10.1016/S0140-6736(20)32656-8.Huang C., Huang L., Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397 (10270): 220–232. DOI: 10.1016/S0140-6736(20)32656-8.Martin-Villares C., Perez Molina-Ramirez C., Bartolome-Benito M. et al. Outcome of 1890 tracheostomies for critical COVID-19 patients: a national cohort study in Spain. Eur. Arch. Otorhinolaryngol. 2021; 278 (5): 1605–1612. DOI: 10.1007/s00405-020-06220-3.Martin-Villares C., Perez Molina-Ramirez C., Bartolome-Benito M. et al. Outcome of 1890 tracheostomies for critical COVID-19 patients: a national cohort study in Spain. Eur. Arch. Otorhinolaryngol. 2021; 278 (5): 1605–1612. DOI: 10.1007/s00405-020-06220-3.Myall K.J., Mukherjee B., Castanheira A.M. et al. Persistent post- COVID-19 interstitial lung disease: An observational study of corticosteroid treatment. Ann. Am. Thorac. Soc. 2021; 18 (5): 799–806. DOI: 10.1513/AnnalsATS.202008-1002OC.Myall K.J., Mukherjee B., Castanheira A.M. et al. Persistent post- COVID-19 interstitial lung disease: An observational study of corticosteroid treatment. Ann. Am. Thorac. Soc. 2021; 18 (5): 799–806. DOI: 10.1513/AnnalsATS.202008-1002OC.Corrigan D., Prucnal C., Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin. Exp. Emerg. Med. 2016; 3 (3): 117–125. DOI: 10.15441/ceem.16.146.Corrigan D., Prucnal C., Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin. Exp. Emerg. Med. 2016; 3 (3): 117–125. DOI: 10.15441/ceem.16.146.Shah A.S., Wong A.W., Hague C.J. et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021; 76 (4): 402–404. DOI: 10.1136/thoraxjnl-2020-216308.Shah A.S., Wong A.W., Hague C.J. et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021; 76 (4): 402–404. DOI: 10.1136/thoraxjnl-2020-216308.Cui S., Chen S., Li X. et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (6): 1421–1424. DOI: 10.1111/jth.14830.Cui S., Chen S., Li X. et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (6): 1421–1424. DOI: 10.1111/jth.14830.Ryan N.M., Birring S.S., Gibson P.G. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9853): 1583–1589. DOI: 10.1016/S0140-6736(12)60776-4.Ryan N.M., Birring S.S., Gibson P.G. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9853): 1583–1589. DOI: 10.1016/S0140-6736(12)60776-4.Vertigan A.E., Kapela S.L., Ryan N.M. et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: A randomized controlled trial. Chest. 2016; 149 (3): 639–648. DOI: 10.1378/chest.15-1271.Vertigan A.E., Kapela S.L., Ryan N.M. et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: A randomized controlled trial. Chest. 2016; 149 (3): 639–648. DOI: 10.1378/chest.15-1271.George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 2020; 8 (8): 807–815. DOI: 10.1016/S2213-2600(20)30225-3.George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 2020; 8 (8): 807–815. DOI: 10.1016/S2213-2600(20)30225-3.Ayoubkhani D., Khunti K., Nafilyan V. et al. Post-Covid syndrome in individuals admitted to hospital with Covid-19: retrospective cohort study. BMJ. 2021; 372: n693. DOI: 10.1136/bmj.n693.Ayoubkhani D., Khunti K., Nafilyan V. et al. Post-Covid syndrome in individuals admitted to hospital with Covid-19: retrospective cohort study. BMJ. 2021; 372: n693. DOI: 10.1136/bmj.n693.Corrado D., Link M. S., Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N. Engl. J. Med. 2017; 376 (1): 61–72. DOI: 10.1056/NEJMra1509267.Corrado D., Link M. S., Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N. Engl. J. Med. 2017; 376 (1): 61–72. DOI: 10.1056/NEJMra1509267.Wu Q., Zhou L., Sun X. et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci. Rep. 2017; 7 (1): 9110. DOI: 10.1038/s41598-017-09536-z.Wu Q., Zhou L., Sun X. et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci. Rep. 2017; 7 (1): 9110. DOI: 10.1038/s41598-017-09536-z.Agarwal A.K., Garg R., Ritch A., Sarkar P. Postural orthostatic tachycardia syndrome. Postgrad. Med. J. 2007; 83 (981): 478–480. DOI: 10.1136/pgmj.2006.055046.Agarwal A.K., Garg R., Ritch A., Sarkar P. Postural orthostatic tachycardia syndrome. Postgrad. Med. J. 2007; 83 (981): 478–480. DOI: 10.1136/pgmj.2006.055046.Lau S.T., Yu W.C., Mok N.S. et al. Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). Int. J. Cardiol. 2005; 100 (1): 167–169. DOI: 10.1016/j.ijcard.2004.06.022.Lau S.T., Yu W.C., Mok N.S. et al. Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). Int. J. Cardiol. 2005; 100 (1): 167–169. DOI: 10.1016/j.ijcard.2004.06.022.Carvalho-Schneider C., Laurent E., Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021; 27 (2): 258–263. DOI: 10.1016/j.cmi.2020.09.052.Carvalho-Schneider C., Laurent E., Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021; 27 (2): 258–263. DOI: 10.1016/j.cmi.2020.09.052.Rajpal S., Tong M. S., Borchers J. et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021; 6 (1): 116–118. DOI: 10.1001/jamacardio.2020.4916.Rajpal S., Tong M. S., Borchers J. et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021; 6 (1): 116–118. DOI: 10.1001/jamacardio.2020.4916.Puntmann V.O., Carerj M.L., Wieters I. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (11): 1265–1273. DOI: 10.1001/jamacardio.2020.3557.Puntmann V.O., Carerj M.L., Wieters I. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (11): 1265–1273. DOI: 10.1001/jamacardio.2020.3557.Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021 [Preprint. Posted: January 30, 2021]. DOI: 10.1101/2021.01.27.21250617.Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021 [Preprint. Posted: January 30, 2021]. DOI: 10.1101/2021.01.27.21250617.Makaronidis J., Firman C., Magee C.G. et al. Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK. BMC Infect. Dis. 2021; 21 (1): 221. DOI: 10.1186/s12879-021-05927-w.Makaronidis J., Firman C., Magee C.G. et al. Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK. BMC Infect. Dis. 2021; 21 (1): 221. DOI: 10.1186/s12879-021-05927-w.Bolay H., Gül A., Baykan B. COVID-19 is a real headache! Headache. 2020; 60 (7): 1415–1421. DOI: 10.1111/head.13856.Bolay H., Gül A., Baykan B. COVID-19 is a real headache! Headache. 2020; 60 (7): 1415–1421. DOI: 10.1111/head.13856.Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021; 27 (4): 601–615. DOI: 10.1038/s41591-021-01283-z.Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021; 27 (4): 601–615. DOI: 10.1038/s41591-021-01283-z.Miskowiak K.W., Johnsen S., Sattler S.M. et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur. Neuropsychopharmacol. 2021; 46: 39–48. DOI: 10.1016/j.euroneuro.2021.03.019.Miskowiak K.W., Johnsen S., Sattler S.M. et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur. Neuropsychopharmacol. 2021; 46: 39–48. DOI: 10.1016/j.euroneuro.2021.03.019.Kincaid K.J., Kung J.C., Senetar A.J. et al. Post-COVID seizure: A new feature of “long-COVID”. eNeurologicalSci. 2021; 23: 100340. DOI: 10.1016/j.ensci.2021.100340.Kincaid K.J., Kung J.C., Senetar A.J. et al. Post-COVID seizure: A new feature of “long-COVID”. eNeurologicalSci. 2021; 23: 100340. DOI: 10.1016/j.ensci.2021.100340.García-Manzanedo S., López de la OlivaCalvo L., Ruiz Álvarez L. Guillain-Barré syndrome after Covid-19 infection. Med. Clin. (Engl. Ed.). 2020; 155 (8): 366. DOI: 10.1016/j.medcle.2020.06.019.García-Manzanedo S., López de la OlivaCalvo L., Ruiz Álvarez L. Guillain-Barré syndrome after Covid-19 infection. Med. Clin. (Engl. Ed.). 2020; 155 (8): 366. DOI: 10.1016/j.medcle.2020.06.019.Raahimi M.M., Kane A., Moore C.E., Alareed A.W. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of “long COVID-19 syndrome”? BMJ Case Rep. 2021; 14 (1): e240178. DOI: 10.1136/bcr-2020-240178.Raahimi M.M., Kane A., Moore C.E., Alareed A.W. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of “long COVID-19 syndrome”? BMJ Case Rep. 2021; 14 (1): e240178. DOI: 10.1136/bcr-2020-240178.Long COVID: understanding the neurological effects. Lancet Neurol. 2021; 20 (4): 247. DOI: 10.1016/S1474-4422(21)00059-4.Long COVID: understanding the neurological effects. Lancet Neurol. 2021; 20 (4): 247. DOI: 10.1016/S1474-4422(21)00059-4.Stefano G.B. Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to long COVID. Med. Sci. Monit. 2021; 27: e931447. DOI: 10.12659/MSM.931447.Stefano G.B. Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to long COVID. Med. Sci. Monit. 2021; 27: e931447. DOI: 10.12659/MSM.931447.Matschke J., Lütgehetmann M., Hagel C. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020; 19 (11): 919–929. DOI: 10.1016/S1474-4422(20)30308-2.Matschke J., Lütgehetmann M., Hagel C. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020; 19 (11): 919–929. DOI: 10.1016/S1474-4422(20)30308-2.Meinhardt J., Radke J., Dittmayer C. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021; 24 (2): 168–175. DOI: 10.1038/s41593-020-00758-5.Meinhardt J., Radke J., Dittmayer C. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021; 24 (2): 168–175. DOI: 10.1038/s41593-020-00758-5.Tandon M., Kataria S., Patel J. et al. A comprehensive systematic review of CSF analysis that defines neurological manifestations of COVID-19. Int. J. Infect. Dis. 2021; 104: 390–397. DOI: 10.1016/j.ijid.2021.01.002.Tandon M., Kataria S., Patel J. et al. A comprehensive systematic review of CSF analysis that defines neurological manifestations of COVID-19. Int. J. Infect. Dis. 2021; 104: 390–397. DOI: 10.1016/j.ijid.2021.01.002.Reichard R.R., Kashani K.B., Boire N.A. et al. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020; 140 (1): 1–6. DOI: 10.1007/s00401-020-02166-2.Reichard R.R., Kashani K.B., Boire N.A. et al. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020; 140 (1): 1–6. DOI: 10.1007/s00401-020-02166-2.Guedj E., Campion J. Y., Dudouet P. et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur. J. Nucl. Med. Mol. Imaging. 2021; 48 (9): 2823–2833. DOI: 10.1007/s00259-021-05215-4.Guedj E., Campion J. Y., Dudouet P. et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur. J. Nucl. Med. Mol. Imaging. 2021; 48 (9): 2823–2833. DOI: 10.1007/s00259-021-05215-4.Silva Andrade B., Siqueira S., de Assis Soares W.R. et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021; 13 (4): 700. DOI: 10.3390/v13040700.Silva Andrade B., Siqueira S., de Assis Soares W.R. et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021; 13 (4): 700. DOI: 10.3390/v13040700.Sher L. Are COVID-19 survivors at increased risk for suicide? Acta Neuropsychiatr. 2020; 32 (5): 270. DOI: 10.1017/neu.2020.21.Sher L. Are COVID-19 survivors at increased risk for suicide? Acta Neuropsychiatr. 2020; 32 (5): 270. DOI: 10.1017/neu.2020.21.Steardo L., Steardo L., Verkhratsky A. Psychiatric face of COVID-19. Transl. Psychiatry. 2020; 10 (1): 261. DOI: 10.1038/s41398-020-00949-5.Steardo L., Steardo L., Verkhratsky A. Psychiatric face of COVID-19. Transl. Psychiatry. 2020; 10 (1): 261. DOI: 10.1038/s41398-020-00949-5.Sher L. The impact of the COVID-19 pandemic on suicide rates. QJM. 2020; 113 (10): 707–712. DOI: 10.1093/qjmed/hcaa202.Sher L. The impact of the COVID-19 pandemic on suicide rates. QJM. 2020; 113 (10): 707–712. DOI: 10.1093/qjmed/hcaa202.ZOE COVID Study. How long does COVID-19 last? Available at: https://covid.joinzoe.com/post/covid-long-termZOE COVID Study. How long does COVID-19 last? Available at: https://covid.joinzoe.com/post/covid-long-termGreenhalgh T., Knight M., A’Court C. et al. Management of postacute Covid-19 in primary care. BMJ. 2020; 370: m3026. DOI: 10.1136/bmj.m3026.Greenhalgh T., Knight M., A’Court C. et al. Management of postacute Covid-19 in primary care. BMJ. 2020; 370: m3026. DOI: 10.1136/bmj.m3026.Raman B., Cassar M. P., Tunnicliffe E. M. et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospi tal discharge. EClinicalMedicine. 2021; 31: 100683. DOI: 10.1016/j.eclinm.2020.100683.Raman B., Cassar M. P., Tunnicliffe E. M. et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospi tal discharge. EClinicalMedicine. 2021; 31: 100683. DOI: 10.1016/j.eclinm.2020.100683.Mazza M. G., De Lorenzo R., Conte C. et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav. Immun. 2020; 89: 594–600. DOI: 10.1016/j.bbi.2020.07.037.Mazza M. G., De Lorenzo R., Conte C. et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav. Immun. 2020; 89: 594–600. DOI: 10.1016/j.bbi.2020.07.037.Davydow D.S., Katon W.J., Zatzick D.F. Psychiatric morbidity and functional impairments in survivors of burns, traumatic injuries, and ICU stays for other critical illnesses: a review of the literature. Int. Rev. Psychiatry. 2009; 21 (6): 531–538. DOI: 10.3109/09540260903343877.Davydow D.S., Katon W.J., Zatzick D.F. Psychiatric morbidity and functional impairments in survivors of burns, traumatic injuries, and ICU stays for other critical illnesses: a review of the literature. Int. Rev. Psychiatry. 2009; 21 (6): 531–538. DOI: 10.3109/09540260903343877.Higgins V., Sohaei D., Diamandis E.P., Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit. Rev. Clin. Lab. Sci. 2021; 58 (5): 297–310. DOI: 10.1080/10408363.2020.1860895.Higgins V., Sohaei D., Diamandis E.P., Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit. Rev. Clin. Lab. Sci. 2021; 58 (5): 297–310. DOI: 10.1080/10408363.2020.1860895.Acharya S., Anwar S., Siddiqui F.S. et al. Renal artery thrombosis in COVID-19. IDCases. 2020; 22: e00968. DOI: 10.1016/j.idcr.2020.e00968.Acharya S., Anwar S., Siddiqui F.S. et al. Renal artery thrombosis in COVID-19. IDCases. 2020; 22: e00968. DOI: 10.1016/j.idcr.2020.e00968.Idilman I.S., Telli Dizman G., Ardali Duzgun S. et al. Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. Eur. Radiol. 2021; 31 (2): 1090–1099. DOI: 10.1007/s00330-020-07155-3.Idilman I.S., Telli Dizman G., Ardali Duzgun S. et al. Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. Eur. Radiol. 2021; 31 (2): 1090–1099. DOI: 10.1007/s00330-020-07155-3.Ramanathan M., Chueng T., Fernandez E., Gonzales-Zamora J. Concomitant renal and splenic infarction as a complication of COVID-19: a case report and literature review. Infez. Med. 2020; 28 (4): 611–615. Available at: https://infezmed.it/media/journal/Vol_28_4_2020_20.pdfRamanathan M., Chueng T., Fernandez E., Gonzales-Zamora J. Concomitant renal and splenic infarction as a complication of COVID-19: a case report and literature review. Infez. Med. 2020; 28 (4): 611–615. Available at: https://infezmed.it/media/journal/Vol_28_4_2020_20.pdfStevens J.S., King K.L., Robbins-Juarez S.Y. et al. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PloS One. 2020; 15 (12): e0244131. DOI: 10.1371/journal.pone.0244131.Stevens J.S., King K.L., Robbins-Juarez S.Y. et al. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PloS One. 2020; 15 (12): e0244131. DOI: 10.1371/journal.pone.0244131.Aminian A., Bena J., Pantalone K.M., Burguera B. Association of obesity with postacute sequelae of COVID-19 (PASC). Diabetes Obes. Metab. 2021; 23 (9): 2183–2188. DOI: 10.1111/dom.14454.Aminian A., Bena J., Pantalone K.M., Burguera B. Association of obesity with postacute sequelae of COVID-19 (PASC). Diabetes Obes. Metab. 2021; 23 (9): 2183–2188. DOI: 10.1111/dom.14454.Suwanwongse K., Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID-19: Causality or coincidence? A report of three cases. J. Med. Virol. 2021; 93 (2): 1150–1153. DOI: 10.1002/jmv.26339.Suwanwongse K., Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID-19: Causality or coincidence? A report of three cases. J. Med. Virol. 2021; 93 (2): 1150–1153. DOI: 10.1002/jmv.26339.Sathish T., Kapoor N., Cao Y. et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes. Metab. 2021; 23 (3): 870–874. DOI: 10.1111/dom.14269.Sathish T., Kapoor N., Cao Y. et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes. Metab. 2021; 23 (3): 870–874. DOI: 10.1111/dom.14269.Sathish T., Anton M.C., Sivakumar T. New-onset diabetes in “long COVID”. J. Diabetes. 2021; 13 (8): 693–694. DOI: 10.1111/1753-0407.13187.Sathish T., Anton M.C., Sivakumar T. New-onset diabetes in “long COVID”. J. Diabetes. 2021; 13 (8): 693–694. DOI: 10.1111/1753-0407.13187.CoviDiab Registry. Available at: https://covidiab.e-dendrite.com/index.htmlCoviDiab Registry. Available at: https://covidiab.e-dendrite.com/index.htmlTee L.Y., Harjanto S., Rosario B.H. COVID-19 complicated by Hashimoto’s thyroiditis. Singapore Med. J. 2021; 62 (5): 265. DOI: 10.11622/smedj.2020106.Tee L.Y., Harjanto S., Rosario B.H. COVID-19 complicated by Hashimoto’s thyroiditis. Singapore Med. J. 2021; 62 (5): 265. DOI: 10.11622/smedj.2020106.Mateu-Salat M., Urgell E., Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J. Endocrinol. Invest. 2020; 43 (10): 1527–1528. DOI: 10.1007/s40618-020-01366-7.Mateu-Salat M., Urgell E., Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J. Endocrinol. Invest. 2020; 43 (10): 1527–1528. DOI: 10.1007/s40618-020-01366-7.Caron P. Thyroiditis and SARS-CoV-2 pandemic: a review. Endocrine. 2021; 72 (2): 326–331. DOI: 10.1007/s12020-021-02689-y.Caron P. Thyroiditis and SARS-CoV-2 pandemic: a review. Endocrine. 2021; 72 (2): 326–331. DOI: 10.1007/s12020-021-02689-y.EurekAlert. COVID-19 can cause atypical thyroid inflammation. Available at: https://www.eurekalert.org/news-releases/787035EurekAlert. COVID-19 can cause atypical thyroid inflammation. Available at: https://www.eurekalert.org/news-releases/787035McMahon D.E., Gallman A.E., Hruza G.J. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect. Dis. 2021; 21 (3): 313–314. DOI: 10.1016/S1473-3099(20)30986-5.McMahon D.E., Gallman A.E., Hruza G.J. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect. Dis. 2021; 21 (3): 313–314. DOI: 10.1016/S1473-3099(20)30986-5.Turkmen D., Altunisik N., Sener S., Colak C. Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. Dermatol. Ther. 2020; 33 (6): e13923. DOI: 10.1111/dth.13923.Turkmen D., Altunisik N., Sener S., Colak C. Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. Dermatol. Ther. 2020; 33 (6): e13923. DOI: 10.1111/dth.13923.Mehta P., Bunker C.B., Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect. Dis. 2021; 21 (7): 912. DOI: 10.1016/S1473-3099(21)00133-X.Mehta P., Bunker C.B., Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect. Dis. 2021; 21 (7): 912. DOI: 10.1016/S1473-3099(21)00133-X.Riphagen S., Gomez X., Gonzalez-Martinez C. et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395 (10237): 1607–1608. DOI: 10.1016/S0140-6736(20)31094-1.Riphagen S., Gomez X., Gonzalez-Martinez C. et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395 (10237): 1607–1608. DOI: 10.1016/S0140-6736(20)31094-1.Dufort E.M., Koumans E.H., Chow E.J. et al. Multisystem inflammatory syndrome in children in New York state. N. Engl. J. Med. 2020; 383 (4): 347–358. DOI: 10.1056/NEJMoa2021756.Dufort E.M., Koumans E.H., Chow E.J. et al. Multisystem inflammatory syndrome in children in New York state. N. Engl. J. Med. 2020; 383 (4): 347–358. DOI: 10.1056/NEJMoa2021756.Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 2020; 383 (4): 334–346. DOI: 10.1056/NEJMoa2021680.Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 2020; 383 (4): 334–346. DOI: 10.1056/NEJMoa2021680.Verdoni L., Mazza A., Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020; 395 (10239): 1771–1778. DOI: 10.1016/S0140-6736(20)31103-X.Verdoni L., Mazza A., Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020; 395 (10239): 1771–1778. DOI: 10.1016/S0140-6736(20)31103-X.McArdle A.J., Vito O., Patel H. et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 2021; 385 (1): 11–22. DOI: 10.1056/NEJMoa2102968.McArdle A.J., Vito O., Patel H. et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 2021; 385 (1): 11–22. DOI: 10.1056/NEJMoa2102968.Son M.B.F., Murray N., Friedman K. et al. Multisystem inflammatory syndrome in children – initial therapy and outcomes. N. Engl. J. Med. 2021; 385 (1): 23–34. DOI: 10.1056/NEJMoa2102605.Son M.B.F., Murray N., Friedman K. et al. Multisystem inflammatory syndrome in children – initial therapy and outcomes. N. Engl. J. Med. 2021; 385 (1): 23–34. DOI: 10.1056/NEJMoa2102605.Molteni E., Sudre C.H., Canas L.S. et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc. Health. 2021; 5 (10): 708–718. DOI: 10.1016/S2352-4642(21)00198-X.Molteni E., Sudre C.H., Canas L.S. et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc. Health. 2021; 5 (10): 708–718. DOI: 10.1016/S2352-4642(21)00198-X.Osmanov I.M., Spiridonova E., Bobkova P. et al. Risk factors for long Covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 2021; 58 (3): 2101341. DOI: 10.1183/13993003.01341-2021.Osmanov I.M., Spiridonova E., Bobkova P. et al. Risk factors for long Covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 2021; 58 (3): 2101341. DOI: 10.1183/13993003.01341-2021.Munblit D., Sigfrid L., Warner J.O. Setting priorities to address research gaps in long-term COVID-19 outcomes in children. JAMA Pediatr. 2021 [Preprint. Posted: August 02, 2021]. DOI: 10.1001/jamapediatrics.2021.2281.Munblit D., Sigfrid L., Warner J.O. Setting priorities to address research gaps in long-term COVID-19 outcomes in children. JAMA Pediatr. 2021 [Preprint. Posted: August 02, 2021]. DOI: 10.1001/jamapediatrics.2021.2281.The Lancet. Facing up to long COVID. Lancet. 2020; 396 (10266): 1861. DOI: 10.1016/S0140-6736(20)32662-3.The Lancet. Facing up to long COVID. Lancet. 2020; 396 (10266): 1861. DOI: 10.1016/S0140-6736(20)32662-3.Alwan N.A. Track COVID-19 sickness, not just positive tests and deaths. Nature. 2020; 584 (7820): 170. DOI: 10.1038/d41586-020-02335-z.Alwan N.A. Track COVID-19 sickness, not just positive tests and deaths. Nature. 2020; 584 (7820): 170. DOI: 10.1038/d41586-020-02335-z.

The authors declare that there are no conflicts of interest present.